Evaluation of the Effects of Caesalpinia crista on Letrozole-Induced Models of Polycystic Ovarian Syndrome.

Abstract

Background Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting reproductive, endocrine, and metabolic functions. This study was designed to validate the claims in Ayurveda regarding the efficacy of Caesalpinia crista (Latakaranj) to treat PCOS. Its seeds are uterine stimulants and ovulation inducersand improve menstrual cycle irregularities. Objectives The present study aimed to evaluate the effects of Caesalpinia crista on reproductive abnormalities, reproductive hormones, and glycemic changes in a letrozole-induced model of PCOS. Material and methods The study was performed in rats with six groups having six rats in each group. The control group was given the vehicle carboxymethylcellulose (CMC) for 21 days orally, followed by normal saline (0.9% NaCl) orally for 15 days. The inducing agent, letrozole, was given to the disease control group and the four treatment groups for 21 days, followed by a treatment period of 15 days with either clomiphene citrate (1.8 mg/kg) orally in the clomiphene group, low-dose (100 mg/kg) Caesalpinia crista, medium-dose (300 mg/kg) Caesalpinia crista, or high-dose (500 mg/kg) Caesalpinia crista. The variables assessed were daily vaginal smears to check for estrous cyclicity, body weight, blood glucose, serum testosterone (T), serum luteinizing hormone (LH), serum follicle-stimulating hormone (FSH), and the number of oocytes from each oviduct. Histopathology of ovaries was also done. Result There was no significant difference between the different groups for body weight and blood glucose. There was a significant difference between the regularity of the estrous cycle of the disease control group and the high-dose Caesalpinia crista (500 mg/kg) group (p<0.01). Hormonal levels of luteinizing hormone (LH) (p<0.05) and follicle-stimulating hormone (FSH) (p<0.05) were significantly raised in the high-doseCaesalpinia crista group, and that of testosterone was significantly decreased (p<0.05) in the high-doseCaesalpinia crista group compared to the disease control group. The number of ova was significantly high in the high-doseCaesalpinia crista group compared to the disease control group (p<0.05). Decreased number of atretic follicles was seen in the high-dose and medium-dose Caesalpinia cristagroup on histopathology, with an increased number of corpus lutea (p<0.05). Conclusion Treatment with Caesalpinia crista in high dose, i.e., 500 mg/kg, significantly improved the reproductive abnormalities (ovulation and menstrual irregularities) and histopathological changes associated with PCOS. It also restored reproductive hormone levels (testosterone, FSH, and LH), which are elevated in PCOS, and normalized the LH/FSH ratio, which is deranged in PCOS.